Skip to Content

Zymergen Inc.

Merger

  • Date:
  • 7/26/2022
  • Company Name:
  • Zymergen Inc.
  • Stock Symbol:
  • ZY
  • Company Name - Buyer:
  • Ginkgo Bioworks
  • Stock Symbol - Buyer:
  • DNA
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 7/25/2022

Case Finder

Locate any case using the tools below.

NEW YORK, July 26, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Zymergen Inc. (NASDAQ: ZY) (“Zymergen”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”).

On July 25, 2022, Zymergen announced that it had entered into an agreement to be acquired by Ginkgo in an all-stock deal valued at $265 million. Pursuant to the merger agreement, Zymergen stockholders will receive a fixed exchange ratio of 0.9179 Ginkgo shares for each Zymergen share. The deal is scheduled to close in the first quarter of 2023.

Bragar Eagel & Squire is concerned that Zymergen’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Zymergen’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Zymergen Inc.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: